Alector, Inc., a clinical stage biotechnology company, focuses on developing therapies that harness the immune system to cure neurodegenerative diseases. Its products in Phase I clinical trial include AL001, a humanized recombinant monoclonal antibody for the treatment of frontotemporal dementia; and AL002 for the treatment of Alzheimer's disease. The company's preclinical stage products comprise AL101 for the treatment of Alzheimer's and Parkinson's diseases; and AL003 for the treatment of Alzheimer's disease. It also has 10 programs under preclinical research stage. The company was founded in 2013 and is headquartered in South San Francisco, California.
Industry, Sector and Symbol
Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
CIKN/A
Phone415-231-5660
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
Employees65
Next Earnings DateN/A
OptionableNot Optionable
Alector (NASDAQ:ALEC) Frequently Asked Questions
What is Alector's stock symbol?
Alector trades on the NASDAQ under the ticker symbol "ALEC."
What price target have analysts set for ALEC?
6 brokerages have issued 1-year price objectives for Alector's stock. Their forecasts range from $26.00 to $27.00. On average, they expect Alector's stock price to reach $26.6667 in the next year. This suggests a possible upside of 41.1% from the stock's current price. View Analyst Price Targets for Alector.
What is the consensus analysts' recommendation for Alector?
6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Alector in the last year. There are currently 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Alector.
Has Alector been receiving favorable news coverage?
News headlines about ALEC stock have been trending somewhat positive recently, InfoTrie Sentiment reports. InfoTrie ranks the sentiment of press coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Alector earned a coverage optimism score of 1.3 on InfoTrie's scale. They also gave news headlines about the company a news buzz of 5.0 out of 10, indicating that recent press coverage is somewhat likely to have an impact on the stock's share price in the near future.
Are investors shorting Alector?
Alector saw a increase in short interest in February. As of February 28th, there was short interest totalling 1,164,492 shares, an increase of 80.0% from the February 15th total of 647,031 shares. Based on an average daily volume of 351,688 shares, the days-to-cover ratio is presently 3.3 days. Approximately 2.8% of the company's stock are short sold. View Alector's Current Options Chain.
Who are some of Alector's key competitors?
Some companies that are related to Alector include Spark Therapeutics (ONCE), argenx (ARGX), Ablynx (ABLYF), China Biologic Products (CBPO), Allogene Therapeutics (ALLO), Repligen (RGEN), Halozyme Therapeutics (HALO), Acceleron Pharma (XLRN), Denali Therapeutics (DNLI), Regenxbio (RGNX), Aerie Pharmaceuticals (AERI), Crispr Therapeutics (CRSP), Atara Biotherapeutics (ATRA), Audentes Therapeutics (BOLD) and Orchard Therapeutics (ORTX).
What other stocks do shareholders of Alector own?
Who are Alector's key executives?
Alector's management team includes the folowing people:
- Dr. Tillman U. Gerngross, Co-Founder & Chairman (Age 55)
- Dr. Arnon Rosenthal, Co-Founder, CEO, Pres & Director (Age 63)
- Dr. Robert Paul, Chief Medical Officer (Age 51)
- Dr. Robert S. King, Chief Devel. Officer (Age 56)
- Dr. Asa Abeliovich M.D., Ph.D., Co-Founder
When did Alector IPO?
(ALEC) raised $177 million in an initial public offering on Thursday, February 7th 2019. The company issued 9,300,000 shares at a price of $18.00-$20.00 per share. Morgan Stanley, BofA Merrill Lynch, Cowen and Barclays served as the underwriters for the IPO.
When did the company's quiet period expire?
Alector's quiet period expired on Tuesday, March 19th. Alector had issued 9,250,000 shares in its IPO on February 7th. The total size of the offering was $175,750,000 based on an initial share price of $19.00. During the company's quiet period, insiders and any underwriters involved in the IPO were restricted from issuing any research reports or earnings estimates for the company because of SEC regulations. Now that the company's quiet period has ended, brokerages that served as underwriters are now able to initiate research on the company.
How do I buy shares of Alector?
Shares of ALEC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Alector's stock price today?
One share of ALEC stock can currently be purchased for approximately $18.90.
How big of a company is Alector?
Alector has a market capitalization of $1.29 billion. Alector employs 65 workers across the globe.
What is Alector's official website?
How can I contact Alector?
Alector's mailing address is 151 OYSTER POINT BLVD. SUITE 300, SOUTH SAN FRANCISCO CA, 94080. The company can be reached via phone at 415-231-5660 or via email at [email protected]
MarketBeat Community Rating for Alector (NASDAQ ALEC)
MarketBeat's community ratings are surveys of what our community members think about Alector and other stocks. Vote "Outperform" if you believe ALEC will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ALEC will underperform the S&P 500 over the long term. You may vote once every thirty days.
